Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | SVP - Legal & General Counsel | March 15, 2022 | March 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 15, 2022 · Filed March 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,408 |
Ending reported balance
After 2022-03-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-03-15 · Exercise / conversion · Acquired 30,818 · Balance 98,605 Row 2 · 2022-03-15 · Exercise / conversion · Acquired 4,803 · Balance 103,408 Row 3 · 2022-03-15 · Exercise / conversion · Acquired 25,196 · Balance 128,604 Row 4 · 2022-03-15 · Sale · Disposed 25,196 · Balance 103,408 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2029-01-31 | Direct | 13,938 |
Reported balance
After 2022-03-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-15 · Exercise / conversion · Disposed 30,818 · Balance 13,938 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.40 · Expires 2030-03-05 | Direct | 4,804 |
Reported balance
After 2022-03-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-15 · Exercise / conversion · Disposed 4,803 · Balance 4,804 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.40 · Expires 2030-03-05 | Direct | 25,197 |
Reported balance
After 2022-03-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-15 · Exercise / conversion · Disposed 25,196 · Balance 25,197 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 50,116 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 18,135 · Balance 0 F2: Shares of restricted stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Represents net amount of shares exchanged after required tax withholding with respect to such vesting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.35 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 56,232 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.27 · Expires 2026-02-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 52,801 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.70 · Expires 2025-02-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 47,500 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.24 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-04 · Disposition to issuer · Disposed 55,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.99 · Expires 2023-05-15 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-04 · Disposition to issuer · Disposed 52,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.90 · Expires 2022-05-23 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-04 · Disposition to issuer · Disposed 21,667 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2021-07-08 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-04 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Represents net amount of shares exchanged after required tax withholding with respect to such vesting.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,196 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · derivative · entry 7 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,197 Underlying: Common Stock · 25,196 shares Expires 2030-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,803 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · derivative · entry 6 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,804 Underlying: Common Stock · 4,803 shares Expires 2030-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 30,818 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · derivative · entry 5 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,938 Underlying: Common Stock · 30,818 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 25,196 | $33.96 | $855,724.19 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · nonDerivative · entry 4 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,408 Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 25,196 | $14.40 | $362,822.40 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · nonDerivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,803 | $14.40 | $69,163.20 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 23:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 30,818 | $7.03 | $216,650.54 |
DisclosureSEC source: 0001061983-22-000077 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 23:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,631 | $36.83 | $170,559.73 |
DisclosureSEC source: 0001061983-22-000070 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,787 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/07/2022 and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,138 | $37.63 Strike: $37.63 | $1,548,022.94 |
DisclosureSEC source: 0001061983-22-000056 · edgardoc.xml · derivative · entry 4 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,138 Underlying: Common Stock · 41,138 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 3,862 | $37.63 Strike: $37.63 | $145,327.06 |
DisclosureSEC source: 0001061983-22-000056 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,862 Underlying: Common Stock · 3,862 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000056 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,418 F2 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 3,457 | $37.63 | $130,086.91 |
DisclosureSEC source: 0001061983-22-000056 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,418 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/02/2022 and does not represent a sale by the reporting person. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000028 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,875 F2 · kind: Comprised of restricted stock units (RSUs) issued upon conversion of certain PSUs granted to the Reporting Person on May 11, 2021. The satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into RSUs of the Issuer. These RSUs will vest in whole on February 16, 2023. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000028 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,750 F1 · kind: On or about May 11, 2021, the Reporting Person was granted performance-based stock units (PSUs) of the Issuer, which upon satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into fully-vested shares of common stock of the Issuer. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,979 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001061983-21-000241 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,265 Underlying: Common Stock · 19,979 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 30, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 19,979 | $35.74 | $713,969.54 |
DisclosureSEC source: 0001061983-21-000241 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,850 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 30, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 19,979 | $7.03 | $140,452.37 |
DisclosureSEC source: 0001061983-21-000241 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 30, 2021. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 23:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,150 | $19.19 | $79,638.50 |
DisclosureSEC source: 0001061983-21-000078 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,850 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/06/2021 and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 34,871 | $19.42 Strike: $19.42 | $677,194.82 |
DisclosureSEC source: 0001061983-21-000061 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,871 Underlying: Common Stock · 34,871 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 10,129 | $19.42 Strike: $19.42 | $196,705.18 |
DisclosureSEC source: 0001061983-21-000061 · edgardoc.xml · derivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,129 Underlying: Common Stock · 10,129 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000061 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant. Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 21:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001061983-20-000143 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,244 Underlying: Common Stock · 10,000 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 21:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001061983-20-000143 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 21:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001061983-20-000143 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 23:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001061983-20-000135 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,244 Underlying: Common Stock · 10,000 shares Expires 2029-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 23:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $23.07 | $230,728.00 |
DisclosureSEC source: 0001061983-20-000135 · edgardoc.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 23:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001061983-20-000135 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on June 23, 2020. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,393 | $14.40 Strike: $14.40 | $725,659.20 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,393 Underlying: Common Stock · 50,393 shares Expires 2030-03-05 F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 9,607 | $14.40 Strike: $14.40 | $138,340.80 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · derivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,607 Underlying: Common Stock · 9,607 shares Expires 2030-03-05 F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 55,244 | $7.03 Strike: $7.03 | $388,365.32 |
DisclosureSEC source: 0001061983-19-000015 · edgardoc.xml · derivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,244 Underlying: Common Stock · 55,244 shares Expires 2029-01-31 F1 · derivative.exercise_date: When the ISO and NQ dated 01/31/2019 are combined for a total grant of 100,000 shares, the option shall vest and become exercisable as to 25,000 shares on 01/31/2020 and the balance of 75,000 divided into equal monthly installments thereafter such that the option shall be 100% vested on 01/31/2023. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 44,756 | $7.03 Strike: $7.03 | $314,634.68 |
DisclosureSEC source: 0001061983-19-000015 · edgardoc.xml · derivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,756 Underlying: Common Stock · 44,756 shares Expires 2029-01-31 F1 · derivative.exercise_date: When the ISO and NQ dated 01/31/2019 are combined for a total grant of 100,000 shares, the option shall vest and become exercisable as to 25,000 shares on 01/31/2020 and the balance of 75,000 divided into equal monthly installments thereafter such that the option shall be 100% vested on 01/31/2023. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 9 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-07-08 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,667 | Not disclosed Strike: $20.90 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 8 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,667 shares Expires 2022-05-23 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 52,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 7 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2023-05-15 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 6 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2024-05-14 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 47,500 | Not disclosed Strike: $40.70 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 5 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,500 shares Expires 2025-02-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 52,801 | Not disclosed Strike: $33.27 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 4 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,801 shares Expires 2026-02-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 56,232 | Not disclosed Strike: $9.35 | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,232 shares Expires 2027-03-02 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 18,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Represents net amount of shares exchanged after required tax withholding with respect to such vesting. F2 · price: Shares of restricted stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Represents net amount of shares exchanged after required tax withholding with respect to such vesting. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:16 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 50,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000081 · wf-form4_152581055657326.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 12:47 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 3,273 | $19.50 | $63,823.50 |
DisclosureSEC source: 0001003642-18-000047 · wf-form4_152027203026483.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,246 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Schlossberg's payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 12:18 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 5,937 | $20.95 | $124,380.15 |
DisclosureSEC source: 0001003642-18-000022 · wf-form4_151975188040385.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,519 F1 · kind: These shares of common stock were withheld by the issuer upon the vesting of two restricted stock awards to satisfy Mr. Schlossberg's payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2017 Filed May 16, 2017 14:56 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 3,488 | $16.80 | $58,598.40 |
DisclosureSEC source: 0001003642-17-000046 · wf-form4_149496100533907.xml · nonDerivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,456 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Schlossberg's payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 14, 2017 Filed May 16, 2017 14:56 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 3,235 | $17.65 | $57,097.75 |
DisclosureSEC source: 0001003642-17-000046 · wf-form4_149496100533907.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,944 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Schlossberg's payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 15:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right to Buy) · Derivative | 56,232 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0001003642-17-000020 · wf-form4_148883092487946.xml · derivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,232 Underlying: Common Stock · 56,232 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option vests in four equal installments beginning on March 2, 2018, which is the first anniversary of the grant date. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 15:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 23,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000020 · wf-form4_148883092487946.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,179 Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 20:22 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 6,014 | $14.05 | $84,496.70 |
DisclosureSEC source: 0001003642-17-000011 · wf-form4_148824492355818.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,907 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of two restricted stock awards to satisfy Mr. Schlossberg's payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.